A new DRUG TRIALS SNAPSHOT is now available
PALYNZIQ is a drug used to lower blood levels of phenylalanine in adults with phenylketonuria (PKU), who have high phenylalanine blood levels on current treatment. Phenylketonuria is a rare inherited disorder that, if left untreated, causes brain damage and disability because of buildup of phenylalanine in the body.
PALYNZIQ is injected under the skin (subcutaneous). The initial dose is injected once weekly for four weeks. Afterwards, the dose is adjusted following a special schedule.